Commentary

Video

Outcomes by Disease Volume: A Subgroup Analysis of the ARANOTE Trial in mHSPC

Author(s):

Daniel J. George, MD,Matthew Smith, MD, PhD

Daniel J. George, MD, and Matthew Smith, MD, PhD, discuss a subgroup analysis from the ARANOTE trial in prostate cancer.

Newsletter

Stay up to date on the most recent and practice-changing oncology data

Subscribe Now!
Related Videos
Daniel J. George, MD, and Matthew Smith, MD, PhD, discuss ongoing research to watch in prostate cancer.
Daniel J. George, MD, and Matthew Smith, MD, PhD, discuss other key prostate cancer data presented at ASCO GU 2025.
Daniel J. George, MD, and Matthew Smith, MD, PhD, discuss data from a real-world analysis for AR inhibitors in nmCRPC.
Daniel J. George, MD, and Matthew Smith, MD, PhD, discuss an age-based subgroup analysis from the ARASENS trial in prostate cancer.
Daniel J. George, MD, and Matthew Smith, MD, PhD, discuss the evolution of treatment for metastatic hormone-sensitive prostate cancer.
William K. Oh, MD
Barry W. Goy, MD
Fred Saad, CQ, MD, FRCS, FCAHS, director, Prostate Cancer Research, Montreal Cancer Institute, Centre Hospitalier de l’Université de Montréal; full professor, Department of Surgery, Université de Montréal; uro-oncologist, Urology Department, University of Montreal Health Center
Floortje J. Backes, MD, discusses ongoing research to watch in ovarian cancer.
Floortje J. Backes, MD, discusses other potential roles for mirvatuximab soravtansine and other antibody-drug conjugates in ovarian cancer.
Related Content
177Lu rhPSMA-10.1 Injection in mCRPC | Image Credit: © Sebastian Kaulitzki – stock.adobe.com
March 13th 2025

177Lu rhPSMA-10.1 Injection Generates Favorable Radiation Dosimetry Data in mCRPC

Neeraj Agarwal, MD
July 17th 2023

FDA Approval Insights: Talazoparib Plus Enzalutamide in HRR Gene–Mutated mCRPC

FDA
March 4th 2025

FDA Approves 2 Denosumab Biosimilars for Osteoporosis and Cancer-Related Bone Disease

Andrew J. Armstrong, MD, MSc
June 15th 2023

FDA Approval Insights: Olaparib Plus Abiraterone in BRCA-Mutated mCRPC

Pedro Barata, MD, MSc, FACP, on prostate cancer
February 24th 2025

Radioligand Therapies and Emerging Targets Drive Innovation in Prostate Cancer Management

Darolutamide in nmCRPC | Image Credit: © Sebastian Kaulitzki – stock.adobe.com Image
February 24th 2025

Darolutamide Provides Clinical Benefits vs Other AR Inhibitors in Black and White Patients With nmCRPC